Schering regenerates with Collateral

Schering AG already had access to Collateral Therapeutics Inc.'s lead compounds, Generx and Genvascor for cardiovascular disease, through a 1996 collaboration. But the pharma company is aiming to build a franchise in regenerative medicine, and last week acquired the U.S. company in order to have more control.

Generx (AdFGF-4) is in Phase IIb/III trials to treat stable exertional angina and Genvascor (Ad5.1FGF-4) is in Phase I trials in peripheral vascular disease...